Recombinant Anti-Ret antibody [EPR2871] - BSA and Azide free (ab214791)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR2871] to Ret - BSA and Azide free
- Suitable for: WB, IP, IHC-P, ICC/IF, ELISA
- Reacts with: Mouse, Rat, Human
Related conjugates and formulations
Overview
-
Product name
Anti-Ret antibody [EPR2871] - BSA and Azide free
See all Ret primary antibodies -
Description
Rabbit monoclonal [EPR2871] to Ret - BSA and Azide free -
Host species
Rabbit -
Tested applications
Suitable for: WB, IP, IHC-P, ICC/IF, ELISAmore details
Unsuitable for: Flow Cyt -
Species reactivity
Reacts with: Mouse, Rat, Human -
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- WB: Neuro-2a, SH-SY5Y and TT cell lysates and mouse and rat brain tissue lysates. IHC-P: Human thyroid gland carcinoma, human gastric carcinoma and mouse colon tissues. ICC/IF: Neuro-2a cells. Flow Cyt: Caco-2 cells. IP: Neuro-2a cell lysate.
-
General notes
ab214791 is the carrier-free version of ab134100.
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. The carrier-free buffer and high concentration allow for increased conjugation efficiency.
This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with <1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C. Do Not Freeze. -
Storage buffer
pH: 7.2
Constituent: PBS -
Carrier free
Yes -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR2871 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
- Anti-Ret antibody [EPR2871] (ab134100)
- Alexa Fluor® 488 Anti-Ret antibody [EPR2871] (ab237105)
- Alexa Fluor® 647 Anti-Ret antibody [EPR2871] (ab311074)
- Alexa Fluor® 594 Anti-Ret antibody [EPR2871] (ab311662)
- Alexa Fluor® 568 Anti-Ret antibody [EPR2871] (ab312936)
- Alexa Fluor® 555 Anti-Ret antibody [EPR2871] (ab313148)
-
Compatible Secondaries
-
Conjugation kits
-
Isotype control
-
Positive Controls
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab214791 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
Use at an assay dependent concentration. Predicted molecular weight: 124 kDa.
|
|
IP |
Use at an assay dependent concentration.
|
|
IHC-P |
Use at an assay dependent concentration. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
|
|
ICC/IF |
Use at an assay dependent concentration.
|
|
ELISA |
Use at an assay dependent concentration.
|
Notes |
---|
WB
Use at an assay dependent concentration. Predicted molecular weight: 124 kDa. |
IP
Use at an assay dependent concentration. |
IHC-P
Use at an assay dependent concentration. Perform heat mediated antigen retrieval before commencing with IHC staining protocol. |
ICC/IF
Use at an assay dependent concentration. |
ELISA
Use at an assay dependent concentration. |
Target
-
Function
Probable receptor with tyrosine-protein kinase activity; important for development. -
Involvement in disease
Defects in RET may be a cause of colorectal cancer (CRC) [MIM:114500].
Defects in RET are a cause of Hirschsprung disease (HSCR) [MIM:142623]. HSCR is a genetic disorder of neural crest development characterized by the absence of intramural ganglion cells in the hindgut, often resulting in intestinal obstruction. Occasionally, MEN2A or FMTC occur in association with HSCR.
Defects in RET are the cause of medullary thyroid carcinoma (MTC) [MIM:155240]. MTC is a rare tumor derived from the C cells of the thyroid. Three hereditary forms are known, that are transmitted in an autosomal dominant fashion: (a) multiple neoplasia type 2A (MEN2A), (b) multiple neoplasia type IIB (MEN2B) and (c) familial MTC (FMTC), which occurs in 25-30% of MTC cases and where MTC is the only clinical manifestation.
Defects in RET are the cause of multiple neoplasia type 2B (MEN2B) [MIM:162300]. MEN2B is an uncommon inherited cancer syndrome characterized by predisposition to MTC and phaeochromocytoma which is associated with marfanoid habitus, mucosal neuromas, skeletal and ophtalmic abnormalities, and ganglioneuromas of the intestine tract. Then the disease progresses rapidly with the development of metastatic MTC and a pheochromocytome in 50% of cases.
Defects in RET are a cause of susceptibility to pheochromocytoma (PCC) [MIM:171300]. A catecholamine-producing tumor of chromaffin tissue of the adrenal medulla or sympathetic paraganglia. The cardinal symptom, reflecting the increased secretion of epinephrine and norepinephrine, is hypertension, which may be persistent or intermittent.
Defects in RET are the cause of multiple neoplasia type 2A (MEN2A) [MIM:171400]; also known as multiple neoplasia type 2 (MEN2). MEN2A is the most frequent form of medullary thyroid cancer (MTC). It is an inherited cancer syndrome characterized by MTC, phaeochromocytoma and/or hyperparathyroidism.
Defects in RET are a cause of thyroid papillary carcinoma (TPC) [MIM:188550]. TPC is a common tumor of the thyroid that typically arises as an irregular, solid or cystic mass from otherwise normal thyroid tissue. Papillary carcinomas are malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. Note=Chromosomal aberrations involving RET are found in thyroid papillary carcinomas. Inversion inv(10)(q11.2;q21) generates the RET/CCDC6 (PTC1) oncogene; inversion inv(10)(q11.2;q11.2) generates the RET/NCOA4 (PTC3) oncogene; translocation t(10;14)(q11;q32) with GOLGA5 generates the RET/GOLGA5 (PTC5) oncogene; translocation t(8;10)(p21.3;q11.2) with PCM1 generates the PCM1/RET fusion; translocation t(6;10)(p21.3;q11.2) with RFP generates the Delta RFP/RET oncogene; translocation t(1;10)(p13;q11) with TRIM33 generates the TRIM33/RET (PTC7) oncogene; translocation t(7;10)(q32;q11) with TRIM24/TIF1 generates the TRIM24/RET (PTC6) oncogene. The PTC5 oncogene has been found in 2 cases of PACT in children exposed to radioactive fallout after Chernobyl. A chromosomal aberration involving TRIM27/RFP is found in thyroid papillary carcinomas. Translocation t(6;10)(p21.3;q11.2) with RET. The translocation generates TRIM27/RET and delta TRIM27/RET oncogenes.
Defects in RET are a cause of renal adysplasia (RADYS) [MIM:191830]; also known as renal agenesis or renal aplasia. Renal agenesis refers to the absence of one (unilateral) or both (bilateral) kidneys at birth. Bilateral renal agenesis belongs to a group of perinatally lethal renal diseases, including severe bilateral renal dysplasia, unilateral renal agenesis with contralateral dysplasia and severe obstructive uropathy.
Defects in RET are a cause of congenital central hypoventilation syndrome (CCHS) [MIM:209880]; also known as congenital failure of autonomic control or Ondine curse. CCHS is a rare disorder characterized by abnormal control of respiration in the absence of neuromuscular or lung disease, or an identifiable brain stem lesion. A deficiency in autonomic control of respiration results in inadequate or negligible ventilatory and arousal responses to hypercapnia and hypoxemia. -
Sequence similarities
Belongs to the protein kinase superfamily. Tyr protein kinase family.
Contains 1 cadherin domain.
Contains 1 protein kinase domain. -
Post-translational
modificationsAutophosphorylated on C-terminal tyrosine residues upon ligand stimulation. Dephosphorylated by PTPRJ on Tyr-905, Tyr-1015 and Tyr-1062. -
Cellular localization
Membrane. - Information by UniProt
-
Database links
- Entrez Gene: 5979 Human
- Entrez Gene: 19713 Mouse
- Entrez Gene: 24716 Rat
- Omim: 164761 Human
- SwissProt: P07949 Human
- SwissProt: P35546 Mouse
- SwissProt: G3V9H8 Rat
- Unigene: 350321 Human
see all -
Alternative names
- C ret antibody
- Cadherin family member 12 antibody
- Cadherin related family member 16 antibody
see all
Images
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human gastric carcinoma tissue labelling Ret with purified ab134100 at a dilution of 1/50. Heat mediated antigen retrieval was performed using EDTA buffer pH 9. ab97051, a HRP-conjugated goat anti-rabbit IgG (H+L) was used as the secondary antibody (1/500). Negative control using PBS instead of primary antibody. Counterstained with hematoxylin.
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab134100).
-
Immunocytochemistry/Immunofluorescence analysis of TT (human thyroid carcinoma epithelial cell) cells labelling Ret with purified ab134100 at a dilution of 1/200. Cells were fixed with 4% paraformaldehyde and permeabilized with 0.1% Triton X-100. ab150077, an Alexa Fluor® 488-conjugated goat anti-rabbit IgG (1/1000) was used as the secondary antibody. DAPI (blue) was used as the nuclear counterstain. Ab195889 Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) (1/200) was used as a counter stain.
-ve control: Caco-2 (PMID: 10811228) cells stained with primary antibody (1/100) and secondary antibody, ab150077, an Alexa Fluor® 488-conjugated goat anti-rabbit IgG (1/1000).
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab134100).
-
ab134100 (purified) at 1/40 immunoprecipitating Ret in Neuro-2a whole cell lysate.
Lane 1 (input): Neuro-2a whole cell lysate (10µg)
Lane 2 (+): ab134100 + Neuro-2a whole cell lysate.
Lane 3 (-): Rabbit monoclonal IgG (ab172730) instead of ab134100 in Neuro-2a whole cell lysate.
For western blotting, ab134100 was used at 1/1000 followed by a HRP-conjugated anti-rabbit IgG (specific to the non-reduced form of IgG, 1/1500).
Blocking buffer and dilution concentration: 5% NFDM/TBST.
We are unsure about the nature of 40kDa to 60kDa bands, they might be the intracellular fragments of Ret.
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab134100).
-
ELISA antigen dose-response curve using purified ab134100 at 0-1000 ng/ml. Antigen concentration of 1000 ng/mL. An Alkaline-Phosphatase-conjugated goat anti-rabbit IgG (H+L) (1/2500) was used as the secondary antibody.
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab134100).
-
Immunocytochemistry/Immunofluorescence analysis of Neuro-2a cells labelling Ret with purified ab134100 at a dilution of 1/100. Cells were fixed with 4% paraformaldehyde and permeabilized with 0.1% Triton X-100. ab150077, an Alexa Fluor® 488-conjugated goat anti-rabbit IgG (1/1000) was used as the secondary antibody. DAPI (blue) was used as the nuclear counterstain. ab7291, a mouse anti-tubulin (1/1000) and ab150120, an Alexa Fluor® 594-conjugated goat anti-mouse IgG (1/1000) were also used.
Control 1: primary antibody (1/100) and secondary antibody, ab150120, an Alexa Fluor® 594-conjugated goat anti-mouse IgG (1/1000).
Control 2: ab7291 (1/1000) and secondary antibody, ab150077, an Alexa Fluor® 488-conjugated goat anti-rabbit IgG (1/1000).
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab134100).
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of mouse colon tissue labelling Ret with unpurified ab134100 at a dilution of 1/50 followed by HRP-conjugated goat anti-rabbit IgG (H&L) (ab97051, 1/500). Counter stained with hematoxylin.
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab134100).
Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human thyroid gland carcinoma tissue labelling Ret with unpurified ab134100 at a dilution of 1/250.
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab134100).
Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
Protocols
Datasheets and documents
-
Datasheet download
Certificate of Compliance
References (7)
ab214791 has been referenced in 7 publications.
- Franz H et al. The histone code reader SPIN1 controls RET signaling in liposarcoma. Oncotarget 6:4773-89 (2015). PubMed: 25749382
- Lee SE et al. Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma. Mod Pathol N/A:N/A (2014). PubMed: 25234288
- Ali HM et al. Effects of siRNA on RET/PTC3 junction oncogene in papillary thyroid carcinoma: from molecular and cellular studies to preclinical investigations. PLoS One 9:e95964 (2014). WB ; Mouse . PubMed: 24759995
- Cyr AR et al. TFAP2C governs the luminal epithelial phenotype in mammary development and carcinogenesis. Oncogene N/A:N/A (2014). PubMed: 24469049
- Wiesner T et al. Kinase fusions are frequent in Spitz tumours and spitzoid melanomas. Nat Commun 5:3116 (2014). Human . PubMed: 24445538
- Licciulli S et al. FRAX597, a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of neurofibromatosis type 2 (NF2)-associated Schwannomas. J Biol Chem 288:29105-14 (2013). WB ; Mouse . PubMed: 23960073
- Fontana X et al. c-Jun in Schwann cells promotes axonal regeneration and motoneuron survival via paracrine signaling. J Cell Biol 198:127-41 (2012). Mouse . PubMed: 22753894